Management of atopic dermatitis in routine clinical practice

Aim: to assess the efficacy and safety of Admera cream, a cosmetic skin solution for atopic dermatitis (AD). Patients and Methods: this open-label, prospective, observational study enrolled 32 patients aged 3–27 (mean age 14.6±2.4 years) with mild- to-moderate AD. Patients were followed up in the outpatient settings over 1 month. Disease severity was evaluated based on the SCORAD index. Xerosis severity was assessed using a visual analogue scale (VAS). A ≥25% reduction of SCORAD index was considered a significant effect. Admera cream was applied at least once daily. Patients were examined at baseline (screening), on days 1 (visit 1), 14±1 (visit 2), and 28±2 (visit 3). Treatment satisfaction was self-assessed using the 5-point Likert scale. A score of 5 illustrates high treatment satisfaction. Results: the mean SCORAD index was 28.4±7.1 at visit 1 and significantly decreased to 18.2±9.2 after 28 days (p<0.001). The mean VAS score was 5.0±1.0 at baseline, 3.5±1.1 after 14 days, and 2.8±1.4 after 28 days (p<0.001). The mean Likert score was 4.5±0.3 in mild AD and 3.7±0.1 in moderate AD. Among 32 participants, 21 patients (65.6%) rated treatment as "excellent,” 10 patients (31.2%) as "good,” and 1 patient (3.1%) as "satisfactory.” No adverse events were reported. Conclusion: Admera cream is characterized by an excellent safety profile and comfort use. This medication is recommended for long-term treatment of AD. KEYWORDS: atopic dermatitis, xerosis, filaggrin, filagrinol, emollient, care product. FOR CITATION: Tataurshchikova N.S., Letyaeva O.I., Rusanova A.S. Management of atopic dermatitis in routine clinical practice. Russian Medical Inquiry. 2022;6(2):72–78 (in Russ.). DOI: 10.32364/2587-6821-2022-6-2-72-78.